Lunaphore and Bethyl Laboratories announce partnership to leverage library of primary antibodies on COMET™ platform and expand spatial biology services
Tweet
Share
E-mailLAUSANNE, Switzerland and WALTHAM, Mass. – May 10, 2023 – 6:00 pm (CEST) – Lunaphore, a Swiss life sciences company developing technology to enable spatial biology in every laboratory, and Bethyl Laboratories, a Fortis Life Sciences company and provider of high-quality reagents and custom services for discovery, development, and manufacturing, today announced a partnership to promote compatibility and expansion of Bethyl’s library of primary antibodies on Lunaphore’s COMET™ platform.
To view the full announcement, including downloadable images, bios, and more, click here.
Key Takeaways:
- This agreement will enable researchers to leverage Bethyl’s highly qualified antibodies and services with the capabilities of Lunaphore’s COMET™, which is the only fully automated high-throughput, hyperplex platform ensuring scalability and reproducibility without the need to conjugate primary antibodies.
- Bethyl has manufactured and validated over 35 antibodies for use on the COMET™ and is continuing to add to this portfolio weekly.
- Lunaphore recently expanded its offerings to become the first universal, end-to-end solution for spatial biology research.
Click image above to view full announcement.
About COMET™
COMET™ is the only fully automated, high-throughput, hyperplex platform ensuring scalability and reproducibility without the need to conjugate primary antibodies. COMET™ provides walk-away automation, integrating staining, imaging, and image preprocessing steps to obtain standard hyperplex images. COMET™ generates highly robust and reproducible data with full tissue preservation, allowing researchers to perform downstream modalities such as H&E or transcriptomics using the same slide. Its superior tissue profiling capabilities facilitate the analysis of 40 different spatial markers in each automated run on a tissue slide. In contrast to other spatial biology solutions, COMET™ works with off-the-shelf, label-free primary antibodies, making panel design much more flexible and faster than any other hyperplex solution. COMET™ works with regular glass slides from standard histology workflows; it is validated for human and mouse samples and is compatible with any other animal sample. The platform can be used for a wide range of research applications, allowing for a dramatic improvement in the understanding of disease pathology. Orders of the new COMET™ version can be placed and will be available for shipment in the upcoming months. To learn more about the COMET™ platform, please visit: https://lunaphore.com/products/comet/
About Lunaphore
Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore provides solutions based on a game-changing chip technology that can extract spatial proteomic and transcriptomic data from tumors and other tissues, transforming any assay into multiplex spatial biology through a streamlined and easily integrated process. Lunaphore empowers researchers in immunology, immuno-oncology, and neuroscience to push the boundaries of scientific discovery and drug development. Lunaphore’s technology enables the identification of biomarker “signatures” with clinical relevance to support the development of diagnostic tools and streamline clinical trials, to ultimately improve patient outcomes. For further information on Lunaphore and its products, please visit https://lunaphore.com.
COMET™ is the only fully automated, high-throughput, hyperplex platform ensuring scalability and reproducibility without the need to conjugate primary antibodies. COMET™ provides walk-away automation, integrating staining, imaging, and image preprocessing steps to obtain standard hyperplex images. COMET™ generates highly robust and reproducible data with full tissue preservation, allowing researchers to perform downstream modalities such as H&E or transcriptomics using the same slide. Its superior tissue profiling capabilities facilitate the analysis of 40 different spatial markers in each automated run on a tissue slide. In contrast to other spatial biology solutions, COMET™ works with off-the-shelf, label-free primary antibodies, making panel design much more flexible and faster than any other hyperplex solution. COMET™ works with regular glass slides from standard histology workflows; it is validated for human and mouse samples and is compatible with any other animal sample. The platform can be used for a wide range of research applications, allowing for a dramatic improvement in the understanding of disease pathology. Orders of the new COMET™ version can be placed and will be available for shipment in the upcoming months. To learn more about the COMET™ platform, please visit: https://lunaphore.com/products/comet/
About Lunaphore
Lunaphore Technologies S.A. is a Swiss company born in 2014 with the vision of enabling spatial biology in every laboratory. Lunaphore provides solutions based on a game-changing chip technology that can extract spatial proteomic and transcriptomic data from tumors and other tissues, transforming any assay into multiplex spatial biology through a streamlined and easily integrated process. Lunaphore empowers researchers in immunology, immuno-oncology, and neuroscience to push the boundaries of scientific discovery and drug development. Lunaphore’s technology enables the identification of biomarker “signatures” with clinical relevance to support the development of diagnostic tools and streamline clinical trials, to ultimately improve patient outcomes. For further information on Lunaphore and its products, please visit https://lunaphore.com.
About Fortis Life Sciences
Fortis Life Sciences, headquartered in Waltham, MA, partners with life sciences and diagnostics companies to design, develop and manufacture custom integrated reagent solutions. Fortis was founded in 2020 with the mission to offer world-class products & services coupled with best-in-class customer experience. Over the course of two years, Fortis has built a portfolio of high-quality products and brands serving various scientific end markets, including diagnostic, therapeutic, and research. Fortis offers CDMO services for commercial diagnostics and therapeutics (under cGMP & ISO:13485 compliance), custom recombinant & VHH antibody development, nanoparticle synthesis & manufacturing, bulk enzyme & recombinant protein production, and other affinity reagents. To learn more about Fortis Life Sciences, please visit https://www.fortislife.com/.
Contacts:
Irene Tamayo
[email protected]
Source: Lunaphore
Distributed by: Reportable, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Victory Sells Tahlo Lake Property in British Columbia
- Bombardier Announces the Election of its Board of Directors
- Australian Oilseeds, Largest APAC Producer of Non-Chemical, Non-GMO “Cold-Processing” Vegetable Oil, Enters into Contract with Woolworths and Costco Australia.
Create E-mail Alert Related Categories
Press Releases, ReportableSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
